R Squared Ltd Takes $111,000 Position in AstraZeneca PLC (NASDAQ:AZN)

R Squared Ltd acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,690 shares of the company’s stock, valued at approximately $111,000.

A number of other institutional investors have also recently bought and sold shares of the business. McClarren Financial Advisors Inc. grew its stake in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in AstraZeneca in the third quarter worth approximately $28,000. Albion Financial Group UT raised its position in AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after acquiring an additional 248 shares in the last quarter. Groupama Asset Managment grew its position in AstraZeneca by 22.9% in the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after acquiring an additional 101,225 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new position in shares of AstraZeneca during the 3rd quarter worth $45,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Trading Up 1.4 %

Shares of NASDAQ:AZN opened at $71.24 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The stock’s 50-day moving average is $66.83 and its 200-day moving average is $73.99. The company has a market cap of $220.92 billion, a P/E ratio of 34.09, a P/E/G ratio of 1.13 and a beta of 0.46. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter last year, the firm posted $0.87 EPS. The company’s revenue was up 18.0% on a year-over-year basis. Equities research analysts predict that AstraZeneca PLC will post 4.12 earnings per share for the current year.

Analyst Ratings Changes

AZN has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.